Home
Abbisko Therapeutics

Abbisko Therapeutics Market Share Analysis for May 2026

Industry: N/A

Domainabbisko.com

Year Founded2016

Employees51 - 200

Annual Revenue$10M - $15M

Abbisko Therapeutics

Abbisko Therapeutics (including company regionals)

abbisko.com

See more website traffic and engagement information

Abbisko Therapeutics Revenue up to May 2026 is 10M - 15M

revenue generated by Abbisko Therapeutics top domains

Abbisko Therapeutics top domains revenue over 3 years

Revenue for Abbisko Therapeutics top domains

abbisko.com10M - 15M

See more with Sales Intelligence

Total visits to Abbisko Therapeutics's top domains

Understand Abbisko Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

abbisko.com615

See more with Sales Intelligence

Avg. visit duration in Abbisko Therapeutics's top domains

Analyze Abbisko Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

abbisko.com--

See more with Sales Intelligence

Avg. pageviews on Abbisko Therapeutics's top domains

See how Abbisko Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

abbisko.com1.12

See more with Sales Intelligence

Abbisko Therapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Abbisko Therapeutics

These are the website technologies, by industry, used by Abbisko Therapeutics top domains

Mobile (3)

Meta Viewport

Advertising (2)

PubMatic

Widget (1)

Baidu Maps

News & Signals from Abbisko Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAbbisko Therapeutics Co., Ltd. attends event 2025 ESMO GI Congress.Abbisko Therapeutics Co., Ltd.today announced that updated results from the phase 2 study of irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the 2025 ESMO GI Congress, taking place in Barcelona, Spain from July 2 to July 5.

NewsMerck KGaA partnered with Abbisko Therapeutics Co., Ltd. on Nov 5th '23.Merck KGaA's agreement with Abbisko grants them the license to commercialize pimicotinib in mainland China, Hong Kong, Macau, and Taiwan, with an option for global distribution.

NewsAbbisko Therapeutics Co., Ltd. is developing pimicotinib within the Licensed Territory.Under the terms of the agreement, Merck will be granted an exclusive license to commercialize products comprising or containing pimicotinib (ABSK021) for all indications in Chinese mainland, Hong Kong, Macau and Taiwan (the "Licensed Territory"), and Abbisko Therapeutics will retain the exclusive rights to develop pimicotinib within the Licensed Territory.